


PHARMACEUTICAL 2022


IDEAYA Biosciences Inc. Rank 93 of 475







PHARMACEUTICAL 2022





The relative strengths and weaknesses of IDEAYA Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IDEAYA Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 66% points. The greatest weakness of IDEAYA Biosciences Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 332% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 250,996 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 45,159 |
| Liabilities, Non-Current | 34,674 |
| Other Assets | 125,588 |
| Other Compr. Net Income | -719 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 506 |
| Property and Equipment | 4,763 |
| Research and Development | 58,158 |
| Revenues | 27,941 |
| Selling, General and Administrative Expense | 20,051 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 381,347 |
| Liabilities | 79,833 |
| Expenses | 78,209 |
| Stockholders Equity | 301,514 |
| Net Income | -49,762 |
| Comprehensive Net Income | -50,122 |
| Economic Capital Ratio | 56% |